Physician profile
Tailar Murphy
NPI 1073143756
$5,036.05
in general payments reported to CMS, 2019-2025
26 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $535 · 2023: $1,669 · 2024: $1,496 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.61 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $563.37 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $479.48 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.21 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $355.37 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $292.40 | 2022-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $280.14 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $215.62 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $209.53 | 2022-2025 | Hetlioz, Fanapt |
| Almatica Pharma LLC | $183.26 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $179.75 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $152.81 | 2022-2025 | Trintellix |
| Corium, LLC | $151.96 | 2022-2024 | Azstarys |
| Alkermes, INC. | $148.19 | 2023-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $130.50 | 2022-2024 | Dyanavel Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $129.67 | 2022-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $73.99 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $67.58 | 2023 | Belsomra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $64.35 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $59.38 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $58.45 | 2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $56.16 | 2023 | Jornay Pm |
| Janssen Scientific Affairs, LLC | $26.87 | 2023 | Spravato |
| Indivior INC. | $21.68 | 2024 | Sublocade |
| Biogen, INC. | $18.77 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $16.95 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tailar Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.